Search

Displaying 1 - 11 of 11

Liquid biopsy and radiomics for liver cancer surveillance

Condition: Cancer / Liver Cancer

Status: Currently Recruiting

This study aims to use new technology involving molecular and imaging tests to help detect liver cancer early in patients. Participants enrolled will participate in it for approximately 5 years. The purpose of this study is to determine if an experimental drug, INT-787, is safe and effective in patients who are hospitalized due to severe alcohol-associated…

Study of Atezolizumab and Bevacizumab Alone or in Combination with Tiragolumab in Patients with Hepatocellular Carcinoma (HCC)

Condition: Cancer / Liver Cancer

Investigator: Linda Wu, MD

Status: Closed

The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo…

Study of NBTRX3 in Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Condition: Cancer / Head and Neck Cancer

Investigator: Brian Henick, MD

Status: Closed

The purpose of this research study is to evaluate the safety and effectiveness (how well the study drug works) of NBTRX3 administered via intratumoral injections (injected directly into tumor) and used together with radiotherapy or radiotherapy combined with cetuximab, and how it compares with radiotherapy alone, or radiotherapy combined with cetuximab.…

Study of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Condition: Cancer / Head and Neck Cancer

Investigator: Matthen Mathew, MD

Status: Closed

The purpose of this study is to study ADU-S100 and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study aims to evaluate how safe and effective this drug combination is at treating your cancer. These drugs are thought to work by interacting with your immune system to in order to more effectively…

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Condition: Cancer / Liver Cancer

Investigator: Yvonne Saenger, MD

Status: Closed

The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body processes the study drug. This is…

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Condition: Cancer / Head and Neck Cancer

Investigator: Matthen Mathew, MD

Status: Closed

There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed…

A 5-Year Study of the Natural History and Management of Patients with Hepatocellular Carcioma (A Type of Liver Cancer)

Condition: Cancer / Liver Cancer

Investigator: Elizabeth Verna, MD

Status: Closed

Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have; learn more about how…

Study of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

Condition: Liver Disease / NASH

Investigator: Julia Wattacheril, MD, MPH

Status: Closed

The Sponsor is conducting this study to find out how safe and effective the investigational drug (alsocalled a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH. Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several…

TARGET-NASH: Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

Condition: Liver Disease / NASH

Investigator: Elizabeth Verna, MD

Status: Closed

This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. The main purpose of this research study is to collect and study information on patients with NAFLD/NASH.The goal of this study is to observe any treatment…

Study of Emricasan in subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Condition: Liver Disease / NASH

Investigator: Elizabeth Verna, MD

Status: Closed

Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and efficacy of a drug called Emricasan (IDN-6556) in reducing the risk…

A study for patients with Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung cancer using study drug MGA271

Condition: Cancer / Head and Neck Cancer

Investigator: Richard Carvajal, MD

Status: Closed

The study involves research about MGA271 in combination with Keytruda. MGA271 targets cancer cells that make a lot of a protein called B7-H3. Another way to say it is that the cells "overexpress" the protein. Very few normal cells express B7-H3. MGA271 is though to work by recognizing cancer cells that overexpress B7-H3 and directing the body…

Status

Medical Condition